Radiometer urgent and acute care testing specialists, will unite with Leica Biosystems and Cepheid to spotlight the breadth and scale of the Danaher Diagnostics portfolio.
RadiometerSep 5 2025 Radiometer urgent and acute care testing specialists, will unite with Leica Biosystems and Cepheid to spotlight the breadth and scale of the Danaher Diagnostics portfolio. This year's unified presence on Stand 109 at IBMS Congress 2025 , demonstrates how Danaher companies work together to provide a comprehensive testing solution that offers a more connected, patient-centerd diagnostic journey - from early detection and diagnosis to monitoring and treatment guidance.
By collaborating with Leica Biosystems and Cepheid, Radiometer's goal is to create a connected diagnostic ecosystem - one that brings together each company's collective strengths to address some of the most urgent challenges faced by providers in healthcare today, advancing precision medicine for future generations of patients. Challenges include fragmented workflows, long turnaround times and operational inefficiencies - all of which ultimately hinder clinical decision making. Through shared connectivity, data insights, and managed service contract models, Danaher companies are collectively helping clinical pathology laboratories meet such challenges with confidence and agility. On Stand 109, Radiometer will discuss its natural synergies within the Danaher Diagnostics portfolio. Providing point-of-care solutions for urgent and acute care settings, its blood gas and immunoassay analysers deliver critical parameters facilitated by its scalable, vendor neutral IT middleware, AQURE - supporting fast clinical decision making. Radiometer will showcase its ABL90 FLEX PLUS compact blood gas analyser with 19 key parameters including Creatinine and Urea - on one 65 µL sample in 35 seconds. To minimize pre-analytical errors with its blood gas analysers, Radiometer offers specially designed capillary sampling tubes and aspirating or self-fill blood gas syringes . Further simplifying bedside blood gas workflows, Radiometer's 1st Automatic workflow solution combines its ABL blood gas analysers, pre-coded safePICO syringes and a sample flow management system, AQURE FLEXLINK. Delivering lab quality results in minutes to accelerate patient flow, Radiometer's simple Drop'n'Go benchtop AQT90 FLEX immunoassay analyser offers POC testing on an extensive range of critical biomarkers, without the need for sample preparation. These include D-Dimer, CRP, Procalcitonin and NT-proBNP. Radiometer's AQURE vendor-neutral IT middleware provides a comprehensive overview of all point of care devices, real-time device and operator management, reports, and interfacing with hospital IT systems, helping with accreditation and compliance requirements. We're excited to be coming together at IBMS to highlight the connected diagnostic ecosystem created by the collaboration between Radiometer, Leica Biosystems and Cepheid and show how our unique strengths combine to support clinical decision-making - from POCT to rapid molecular and tissue analysis, IBMS is an opportunity to connect, learn, and collaborate with healthcare professionals. As part of our ongoing commitment to sustainability, we'll plant one tree for every visitor scanned at Stand 109. So, please join us, and together we can make a difference to the planet."
Blood Gas Diagnostic Diagnostics Healthcare Immunoassay Testing Solution
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
First patient treated by new LINAC machine at Royal Shrewsbury HospitalThe first patient has been treated by a new linear accelerator machine (also known as a LINAC) at the Trust, which runs the county’s acute hospitals.
Read more »
ChatGPT to sound alarm if children seeking life advice show 'acute distress'The move comes after a teenager took his own life after speaking with ChatGPT, with his parents launching a lawsuit against OpenAI.
Read more »
Early aspirin discontinuation safe after complete revascularization in acute MIAmong low-risk patients with acute MI who underwent early complete revascularization and received one month of dual antiplatelet therapy (DAPT), P2Y12 inhibitor monotherapy was noninferior to continued DAPT for adverse cardiovascular and cerebrovascular events, while reducing bleeding risk.
Read more »
Dual antiplatelet therapy shows no benefit over aspirin after CABG in patients with acute coronary syndromeDual antiplatelet therapy (DAPT) was not more effective than aspirin alone for the prevention of major adverse cardiovascular events and increased major bleeding in patients with acute coronary syndrome (ACS) who underwent coronary artery bypass grafting (CABG), according to late-breaking research presented in a Hot Line session today at ESC...
Read more »
Trial compares the use of blood thinners after stenting in patients with acute coronary syndromesNoninferiority was not demonstrated for death and ischemic events between P2Y12 inhibitor monotherapy and dual antiplatelet therapy (DAPT) given for 12 months after stenting in patients with acute coronary syndromes (ACS), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in...
Read more »
Martha's rule rolled out to every acute hospital in EnglandThe scheme was set up after the death of 13-year-old Martha Mills, who developed sepsis while under the care of the NHS in 2021. An inquest ruled she may have been saved had doctors identified concerns sooner.
Read more »